01 Apr 2026

CRC Research Update — April 01, 2026

Creator: The CRC Digest
Published: 2026-04-01T11:42:27Z

Today's colorectal cancer research highlights

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

Signal Key

TRIAL DATA clinical trial results, efficacy data, survival endpoints TREATMENT new treatment options, regimen changes, combination therapies REGULATORY FDA/EMA approvals, guideline updates, NCCN/ESMO changes RESEARCH cancer biology, biomarker discoveries, resistance pathways SCREENING screening, colonoscopy guidelines, liquid biopsy, molecular profiling LIVING WITH CRC survivorship, quality of life, side effects, patient decision-making, caregiver support

CRC Research Update

Early-childhood bacterial exposure may seed colorectal cancer decades before diagnosis
Researchers propose that mutagen-producing bacteria in early childhood may imprint oncogenic mutations in developing colorectal tissue, initiating tumorigenesis years before clinical detection and potentially explaining the rise in early-onset cases. (Cancer Discovery)
Circulating tumor cells show promise as noninvasive screening alternative
Blood-based detection of circulating tumor cells is being evaluated as a convenient screening method to complement colonoscopy, potentially addressing limitations in current stool-based tests like FIT. (Cancer Epidemiology, Biomarkers & Prevention)
Circulating tumor DNA timing matters for predicting outcomes after surgery
A study examined ctDNA as a prognostic marker across three critical windows: immediately after surgery, after completing adjuvant therapy, and during surveillance in localized colorectal cancer patients. (Journal of the National Comprehensive Cancer Network)
ETV7 protein drives 5-FU resistance through immune pathway activation
Elevated ETV7 expression in CRC promotes resistance to 5-fluorouracil chemotherapy by upregulating CXCL1, which triggers neutrophil extracellular trap formation and enhances tumor cell survival and invasion. (Communications Biology)

🔬 Under 50 Spotlight

Research relevant to early-onset and younger CRC patients

Early-onset CRC rising in Switzerland despite overall decline
A nationwide study from 1980–2021 shows colorectal cancer incidence declining in older adults but increasing in those under 50, mirroring global trends. (European Journal of Cancer)
Fastest increases in CRC occur below age 45, especially rectal cancer
While screening at age 45 may help, the steepest rise in early-onset cases is among those under 45, where population-wide screening is not cost-effective. (Cancer Epidemiology, Biomarkers & Prevention)

🔎 Screening Watch

Screening guidelines, early detection, and prevention advances

Fecal hemoglobin levels may help triage patients for colon capsule endoscopy
Researchers found that stratifying patients by fecal hemoglobin concentration could reduce re-investigation rates after colon capsule endoscopy, offering a potential alternative to colonoscopy in screening populations. (Therapeutic Advances in Gastroenterology)

Research continues to uncover why early-onset CRC is rising and how we can detect it sooner. Stay informed and discuss any concerns with your care team.

CRC Research Update

Subscribe to The CRC Digest